MAZENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Maze Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$29.70+2.17 (+7.88%)
Close on Oct 19, 2026
- Market cap
- $1.75B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
59M of 56M shares
Institutional holders
162
39 new, 39 sold out
Net institutional buying
10M
In Q2 2026
Insider trades, 12 months
0 buys · 91 sales
Net sold $22.10M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Third Rock Ventures IV, L.P. | 6,073,958 | 13.90% | 13G (passive) | Jan 31, 2025 |
| Third Rock Ventures GP IV, L.P. | 4,473,958 | 9.30% | 13G (passive) amendment | Dec 31, 2025 |
| James N. Topper | 4,451,339 | 10.20% | 13G (passive) amendment | Apr 25, 2025 |
| Fhmlsp, L.P. | 4,342,266 | 9.00% | 13G (passive) amendment | Dec 31, 2025 |
| Patrick J. Heron | 4,129,000 | 9.40% | 13G (passive) amendment | Mar 31, 2025 |
| Kristina Burow | 4,120,053 | 9.40% | 13G (passive) | Mar 31, 2025 |
| Deep Track Biotechnology Master Fund, Ltd. | 3,948,910 | 9.02% | 13G (passive) amendment | Jun 30, 2025 |
| Fhmlsp, L.L.C. | 3,352,915 | 7.70% | 13G (passive) amendment | Jun 30, 2025 |
| David Kroin | 3,023,484 | 6.91% | 13G (passive) | Jan 31, 2025 |
| BlackRock, Inc. | 2,978,114 | 5.40% | 13G (passive) | Jun 30, 2026 |
| Janus Henderson Group PLC | 2,858,876 | 5.80% | 13G (passive) amendment | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of MAZE | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 5,032,915 | 9.06% | $150.18M | +465,641 | 3.27% |
| Trv Gp Iv, LLC | 4,473,958 | 8.05% | $133.50M | – | 52.63% |
| ARCH Venture Management, LLC | 4,120,053 | 7.42% | $122.98M | – | 11.18% |
| Deep Track Capital, LP | 3,732,569 | 6.72% | $111.38M | +255,007 | 1.62% |
| BlackRock, Inc. | 3,502,841 | 6.31% | $104.52M | +932,416 | 0.00% |
| Jupiter Topco LLC | 3,408,045 | 6.14% | $101.76M | New | 0.04% |
| T. Rowe Price Investment Management, Inc. | 2,603,682 | 4.69% | $77.69K | New | 0.05% |
| Logos Global Management LP | 1,935,000 | 3.48% | $57.74M | +700,000 | 2.49% |
| Vanguard Capital Management LLC | 1,778,222 | 3.20% | $53.06M | +342,566 | 0.00% |
| a16z Capital Management, L.L.C. | 1,702,225 | 3.06% | $50.79M | – | 0.36% |
| VR Adviser, LLC | 1,602,034 | 2.88% | $47.80M | – | 1.45% |
| Alphabet Inc. | 1,388,583 | 2.50% | $41.44M | – | 0.04% |
| Braidwell LP | 1,140,040 | 2.05% | $34.02M | New | 1.26% |
| Farallon Capital Management LLC | 1,107,814 | 1.99% | $33.06M | +734,814 | 0.15% |
| FMR LLC | 1,056,959 | 1.90% | $31.54M | +192,745 | 0.00% |
| General Catalyst Group Management, LLC | 1,035,910 | 1.86% | $30.91M | – | 16.40% |
| State Street Corp | 997,533 | 1.80% | $29.77M | +360,811 | 0.00% |
| JPMorgan Chase & Co | 964,011 | 1.74% | $28.00M | +905,565 | 0.00% |
| Driehaus Capital Management LLC | 954,886 | 1.72% | $28.49M | +318,724 | 0.17% |
| Trv Gp V, LLC | 950,800 | 1.71% | $28.37M | – | 5.69% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 162 | 59M | 100.0% | 39 / 66 | 38 / 39 | 17M | 8M |
| Q1 2026 | 165 | 52M | 93.0% | 49 / 58 | 36 / 25 | 11M | 6M |
| Q4 2025 | 143 | 48M | 87.1% | 57 / 46 | 20 / 8 | 10M | 5M |
| Q3 2025 | 94 | 43M | 77.4% | 23 / 39 | 15 / 3 | 8M | 4M |
| Q2 2025 | 75 | 39M | 69.9% | 14 / 25 | 14 / 7 | 2M | 3M |
| Q1 2025 | 68 | 40M | 72.1% | 68 / 0 | 0 / 0 | 40M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of MAZE | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,411,990 | 2.54% | $42.13M | 0.00% | Jun 30, 2026 |
| T. Rowe Price Capital Appreciation Fund | 978,329 | 1.76% | $29.19M | 0.04% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 920,284 | 1.66% | $27.46M | 0.03% | Jun 30, 2026 |
| Select Biotechnology Portfolio | 739,660 | 1.33% | $19.57M | 0.37% | May 31, 2026 |
| JPMorgan Small Cap Growth Fund | 421,350 | 0.76% | $12.57M | 0.48% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 385,642 | 0.69% | $10.38M | 0.03% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 325,513 | 0.59% | $9.71M | 0.01% | Jun 30, 2026 |
| T. Rowe Price Small-Cap Stock Fund, Inc. | 295,465 | 0.53% | $8.82M | 0.09% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 276,075 | 0.50% | $8.24M | 0.05% | Jun 30, 2026 |
| T. Rowe Price Small-Cap Value Fund, Inc. | 274,185 | 0.49% | $8.18M | 0.08% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF | 265,830 | 0.48% | $7.93M | 1.85% | Jun 30, 2026 |
| iShares Biotechnology ETF | 242,763 | 0.44% | $7.24M | 0.08% | Jun 30, 2026 |
| JNL/T. Rowe Price Capital Appreciation Fund | 212,255 | 0.38% | $6.33M | 0.04% | Jun 30, 2026 |
| BlackRock Health Sciences Opportunities Portfolio | 184,453 | 0.33% | $4.88M | 0.08% | May 29, 2026 |
| T. Rowe Price Institutional Small-Cap Stock Fund | 158,415 | 0.29% | $4.73M | 0.09% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Jason V. Coloma | Chief Executive Officer, Director | 268,997 | 0.48% | Sep 4, 2026 |
| Harold Bernstein | President, R&D & CMO | 0 | – | Sep 8, 2026 |
| Atul Dandekar | CSBO | 32,316 | 0.06% | Sep 4, 2026 |
| Phillips Courtney | GC and Corp. Secretary | 7,007 | 0.01% | Sep 4, 2026 |
| Amy Bachrodt | SVP, Finance | 15,465 | 0.03% | Apr 2, 2026 |
| Misbah Tahir | Chief Financial Officer | – | – | Mar 3, 2026 |
| Paula A. Johnson | Director | – | – | Aug 17, 2026 |
| Sophie Kornowski | Director | – | – | Aug 17, 2026 |
| Richard H. Scheller | Director | 0 | – | Jun 10, 2026 |
| Herve Hoppenot | Director | – | – | Jun 10, 2026 |
| Jonathan E. Lim | Director | 328,700 | 0.59% | Jun 10, 2026 |
| Daniel K. Spiegelman | Director | – | – | Jun 10, 2026 |
| Charles J. Homcy | Director | 38,535 | 0.07% | Jun 10, 2026 |
| Nancy C. Andrews | Director | – | – | Jun 10, 2026 |
| Neil Kumar | Director | – | – | Mar 31, 2026 |
| Catherine A. Sohn | Director | 20,744 | 0.04% | Jan 8, 2026 |
| Sekar Kathiresan | Director | 103,723 | 0.19% | Sep 24, 2025 |
| Neil Exter | Director | – | – | Sep 24, 2025 |
| James Brush | Director | – | – | Jan 30, 2025 |
| Jeffrey K. Tong | Director | – | – | Jan 30, 2025 |
| Alan Colowick | Director | – | – | Jan 30, 2025 |
| Third Rock Ventures GP V, LP | 10% owner | 5,424,758 | 9.77% | Nov 5, 2025 |
| Third Rock Ventures V, L.P. | 10% owner | – | – | Nov 5, 2025 |
| Third Rock Ventures GP IV, L.P. | 10% owner | – | – | Nov 5, 2025 |
| Trv Gp Iv, Llc | 10% owner | – | – | Nov 5, 2025 |
| Third Rock Ventures IV, L.P. | 10% owner | 7,024,758 | 12.65% | Nov 5, 2025 |
| Trv Gp V, Llc | 10% owner | 311,170 | 0.56% | Nov 5, 2025 |
| Kristina Burow | 10% owner | – | – | Jan 30, 2025 |
| Robert Nelsen | 10% owner | – | – | Jan 30, 2025 |
| Steven Gillis | 10% owner | – | – | Jan 30, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Harold Bernstein President, R&D & CMO | Sep 4, 2026 | Sale(10b5-1 plan) | −9,705 | $26.22 | $254.47K | 0 |
| Jason V. Coloma Chief Executive Officer, Director | Sep 3, 2026 | Sale | −11,282 | $26.01 | $293.44K | 27,491 |
| Jason V. Coloma Chief Executive Officer, Director | Sep 3, 2026 | Sale | −129 | $25.77 | $3.32K | 27,362 |
| Atul Dandekar CSBO | Sep 3, 2026 | Sale | −36 | $25.81 | $929 | 32,316 |
| Atul Dandekar CSBO | Sep 3, 2026 | Sale | −3,207 | $26.01 | $83.41K | 32,352 |
| Phillips Courtney GC and Corp. Secretary | Sep 3, 2026 | Sale | −22 | $25.78 | $567 | 7,007 |
| Phillips Courtney GC and Corp. Secretary | Sep 3, 2026 | Sale | −1,990 | $26.01 | $51.76K | 7,029 |
| Harold Bernstein President, R&D & CMO | Sep 3, 2026 | Sale | −5,130 | $26.01 | $133.43K | 9,764 |
| Harold Bernstein President, R&D & CMO | Sep 3, 2026 | Sale | −59 | $25.78 | $1.52K | 9,705 |
| Jason V. Coloma Chief Executive Officer, Director | Sep 2, 2026 | Sale | −9,852 | $26.38 | $259.90K | 40,148 |
| Jason V. Coloma Chief Executive Officer, Director | Sep 2, 2026 | Sale | −1,375 | $27.12 | $37.29K | 38,773 |
| Atul Dandekar CSBO | Sep 2, 2026 | Sale | −391 | $27.12 | $10.60K | 35,559 |
| Atul Dandekar CSBO | Sep 2, 2026 | Sale | −2,800 | $26.38 | $73.86K | 35,950 |
| Phillips Courtney GC and Corp. Secretary | Sep 2, 2026 | Sale | −1,738 | $26.38 | $45.85K | 9,262 |
| Phillips Courtney GC and Corp. Secretary | Sep 2, 2026 | Sale | −243 | $27.12 | $6.59K | 9,019 |
| Harold Bernstein President, R&D & CMO | Sep 2, 2026 | Sale | −4,481 | $26.38 | $118.21K | 15,519 |
| Harold Bernstein President, R&D & CMO | Sep 2, 2026 | Sale | −625 | $27.12 | $16.95K | 14,894 |
| Atul Dandekar CSBO | Sep 1, 2026 | Option exercise | +12,500 | – | – | 38,750 |
| Jason V. Coloma Chief Executive Officer, Director | Sep 1, 2026 | Sale(10b5-1 plan) | −31,908 | $26.29 | $838.86K | 223,355 |
| Jason V. Coloma Chief Executive Officer, Director | Sep 1, 2026 | Option exercise | +50,000 | – | – | 50,000 |
| Jason V. Coloma Chief Executive Officer, Director | Sep 1, 2026 | Sale(10b5-1 plan) | −2,593 | $26.31 | $68.22K | 18,151 |
| Phillips Courtney GC and Corp. Secretary | Sep 1, 2026 | Option exercise | +11,000 | – | – | 11,000 |
| Harold Bernstein President, R&D & CMO | Sep 1, 2026 | Option exercise | +20,000 | – | – | 20,000 |
| Harold Bernstein President, R&D & CMO | Sep 1, 2026 | Sale(10b5-1 plan) | −16,141 | $26.36 | $425.48K | 0 |
| Harold Bernstein President, R&D & CMO | Sep 1, 2026 | Option exercise | +16,141 | $10.42 | $168.19K | 16,141 |
| Atul Dandekar CSBO | Aug 28, 2026 | Option exercise | +7,500 | $10.42 | $78.15K | 33,750 |
| Atul Dandekar CSBO | Aug 28, 2026 | Sale(10b5-1 plan) | −7,500 | $27.58 | $206.85K | 26,250 |
| Harold Bernstein President, R&D & CMO | Aug 13, 2026 | Option exercise | +16,142 | $10.42 | $168.20K | 16,142 |
| Harold Bernstein President, R&D & CMO | Aug 13, 2026 | Sale(10b5-1 plan) | −16,142 | $27.61 | $445.68K | 0 |
| Jason V. Coloma Chief Executive Officer, Director | Aug 3, 2026 | Sale(10b5-1 plan) | −1,604 | $27.09 | $43.45K | 255,263 |
| Jason V. Coloma Chief Executive Officer, Director | Aug 3, 2026 | Sale(10b5-1 plan) | −30,304 | $26.71 | $809.42K | 256,867 |
| Jason V. Coloma Chief Executive Officer, Director | Aug 3, 2026 | Sale(10b5-1 plan) | −154 | $27.09 | $4.17K | 20,744 |
| Jason V. Coloma Chief Executive Officer, Director | Aug 3, 2026 | Sale(10b5-1 plan) | −2,439 | $26.71 | $65.15K | 20,898 |
| Atul Dandekar CSBO | Jul 29, 2026 | Sale(10b5-1 plan) | −7,100 | $27.31 | $193.90K | 26,650 |
| Atul Dandekar CSBO | Jul 29, 2026 | Sale(10b5-1 plan) | −400 | $27.89 | $11.16K | 26,250 |
| Atul Dandekar CSBO | Jul 29, 2026 | Option exercise | +7,500 | $10.42 | $78.15K | 33,750 |
| Jason V. Coloma Chief Executive Officer, Director | Jul 1, 2026 | Sale(10b5-1 plan) | −30,311 | $29.95 | $907.81K | 288,768 |
| Jason V. Coloma Chief Executive Officer, Director | Jul 1, 2026 | Sale(10b5-1 plan) | −2,593 | $29.98 | $77.74K | 23,337 |
| Jason V. Coloma Chief Executive Officer, Director | Jul 1, 2026 | Sale(10b5-1 plan) | −1,597 | $30.44 | $48.61K | 287,171 |
| Harold Bernstein President, R&D & CMO | Jul 1, 2026 | Sale(10b5-1 plan) | −13,409 | $29.87 | $400.53K | 1,200 |
| Harold Bernstein President, R&D & CMO | Jul 1, 2026 | Option exercise | +14,609 | $10.42 | $152.23K | 14,609 |
| Harold Bernstein President, R&D & CMO | Jul 1, 2026 | Sale(10b5-1 plan) | −1,200 | $30.34 | $36.41K | 0 |
| Atul Dandekar CSBO | Jun 29, 2026 | Option exercise | +7,500 | $10.42 | $78.15K | 33,750 |
| Atul Dandekar CSBO | Jun 29, 2026 | Sale(10b5-1 plan) | −7,500 | $28.02 | $210.15K | 26,250 |
| Jason V. Coloma Chief Executive Officer, Director | Jun 23, 2026 | Sale(10b5-1 plan) | −23,865 | $26.05 | $621.68K | 319,079 |
| Jason V. Coloma Chief Executive Officer, Director | Jun 22, 2026 | Sale(10b5-1 plan) | −2,040 | $26.00 | $53.04K | 25,930 |
| Jason V. Coloma Chief Executive Officer, Director | Jun 22, 2026 | Sale(10b5-1 plan) | −1,953 | $26.00 | $50.78K | 342,944 |
| Jason V. Coloma Chief Executive Officer, Director | Jun 1, 2026 | Sale(10b5-1 plan) | −553 | $26.24 | $14.51K | 27,970 |
| Jason V. Coloma Chief Executive Officer, Director | Jun 1, 2026 | Sale(10b5-1 plan) | −6,090 | $26.20 | $159.56K | 344,897 |
| Harold Bernstein President, R&D & CMO | Jun 1, 2026 | Sale(10b5-1 plan) | −13,253 | $25.57 | $338.88K | 1,600 |
| Harold Bernstein President, R&D & CMO | Jun 1, 2026 | Option exercise | +14,853 | $10.42 | $154.77K | 14,853 |
| Harold Bernstein President, R&D & CMO | Jun 1, 2026 | Sale(10b5-1 plan) | −1,600 | $26.36 | $42.18K | 0 |
| Atul Dandekar CSBO | May 29, 2026 | Sale(10b5-1 plan) | −7,500 | $26.34 | $197.55K | 24,808 |
| Atul Dandekar CSBO | May 29, 2026 | Option exercise | +7,500 | $10.42 | $78.15K | 32,308 |
| Jason V. Coloma Chief Executive Officer, Director | May 26, 2026 | Sale(10b5-1 plan) | −25,582 | $26.02 | $665.64K | 350,987 |
| Jason V. Coloma Chief Executive Officer, Director | May 22, 2026 | Sale(10b5-1 plan) | −2,478 | $26.00 | $64.43K | 28,523 |
| Jason V. Coloma Chief Executive Officer, Director | May 22, 2026 | Sale(10b5-1 plan) | −4,504 | $26.00 | $117.10K | 376,569 |
| Jason V. Coloma Chief Executive Officer, Director | May 15, 2026 | Sale(10b5-1 plan) | −1,822 | $26.00 | $47.37K | 381,073 |
| Jason V. Coloma Chief Executive Officer, Director | May 15, 2026 | Sale(10b5-1 plan) | −116 | $26.00 | $3.02K | 31,001 |
| Harold Bernstein President, R&D & CMO | May 14, 2026 | Option exercise | +15,000 | $10.42 | $156.30K | 15,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Jason V. Coloma Officer | Oct 1, 2026 | 34,501 | $933.25K | Oct 1, 2026 | Gift |
| Bernstein Harold Officer | Oct 1, 2026 | 16,141 | $438.71K | Oct 1, 2026 | Exercise of Stock Options |
| Bernstein Harold Officer | Sep 4, 2026 | 9,705 | $251.07K | Sep 4, 2026 | Restricted Stock Units |
| Phillips Courtney Officer | Sep 2, 2026 | 4,144 | $110.00K | Sep 2, 2026 | Restricted Stock Unit Vesting |
| Dandekar Atul Officer | Sep 2, 2026 | 6,679 | $177.20K | Sep 2, 2026 | Restricted Stock Unit Vesting |
| V. Coloma Jason Officer | Sep 2, 2026 | 23,497 | $623.40K | Sep 2, 2026 | Restricted Stock Unit Vesting |
| Bernstein Harold Officer | Sep 2, 2026 | 10,685 | $283.50K | Sep 2, 2026 | Restricted Stock Unit Vesting |
| Jason V. Coloma Officer | Sep 1, 2026 | 34,501 | $908.07K | Sep 1, 2026 | Gift |
| Jason V. Coloma Officer | Aug 3, 2026 | 34,501 | $922.56K | Aug 3, 2026 | Gift |
| Dandekar Atul Officer | Jul 29, 2026 | 22,500 | $627.30K | Jul 29, 2026 | Exercise of Stock Options |
| Bernstein Harold Officer | Jul 1, 2026 | 46,892 | $1.40M | Jul 1, 2026 | Exercise of Stock Options |
| Jason V. Coloma Officer | Jul 1, 2026 | 34,501 | $1.03M | Jul 1, 2026 | Gift |
| Jason V. Coloma Officer | Jun 1, 2026 | 34,501 | $908.07K | Jun 1, 2026 | Gift |
| Jason V. Coloma Officer | May 15, 2026 | 34,502 | $895.33K | May 15, 2026 | Gift |
| Dandekar Atul Officer | Mar 30, 2026 | 30,000 | $911.40K | Mar 30, 2026 | Exercise of Stock Options |